The Contribution of Auer Rods to the Classification and Prognosis of Myelodysplastic Syndromes

References

• McCrae T. Acute lymphatic leukaemia, with a report of five cases. Br. Med. J. 1905; 404–408, February 25
   PubMedGoogle Scholar
• Auer J. Some hitherto undescribed structures found in the large lymphocytes of a case of acute leukaemia. Am. J. Med. Sci. 1906; 131: 1002–1015
   Google Scholar
• Ottenberg R. Observations on acute leukemia with special reference to Auer's bodies. Am. J. Med. Sci. 1909; 138: 562–567
   Google Scholar
• Isaac S., Cobliner S. über mikrolymphozytäre typen akuter myeloischer leukamien. Folia Haematol. 1910; 10: 459–474
   Google Scholar
• Chrosrojeff G.P. Myelosis aleucaemica acuta micromyeloblastica. Folia Haematol. 1915; 20: 33–56
   Google Scholar
• Jochmann, Blühdorn. Akute myeloblastenleukämie. Folia Haematol. 1911; 12: 181–193
   Google Scholar
• Thro W.C. Some unusual blood cells in diseases of bone marrow origin. J. Med. Res. 1918; 38: 385–391
   PubMedGoogle Scholar
• Rosenthal N. Studies on the oxidase reaction of the cells in normal and leukemic blood. Arch. Int. Med 1917; 20: 184–197
   Google Scholar
• Aibara N. Beitrage zur kenntnis des Auerkorpers. Nagoya J. Med. Sci., S 1931; 148
   Google Scholar
• Goodwin A.F. Some observations on Auer bodies an acute myelogenous leukemia. Folia Haematol. 1934; 51: 359–366
   Google Scholar
• Richter M.N. The presence of Auer bodies in leukemic tissues. Arch. Int. Med. 1923; 31: 677–685
   Google Scholar
• Luzzatto A.M. Sull anemia grave megaloblastica senza reperto ematologico corrispondente (anemia pseudoplastica). Riv. Ven. 1907; 41: 19–212
   Google Scholar
• Mallarmé J. Les débuts hématologiques des leucoses malignes. Sang. 1949; 20: 429–433
   PubMedGoogle Scholar
• Hamilton-Paterson J.L. Pre-leukaemic anaemia. Acta Haematol. 1949; 2: 309–316
   PubMed Web of Science ®Google Scholar
• Block M., Jacobson L.O., Bernard W.F. Preleukemic acute human leukemia. J. Am. Med. Assoc 1953; 152: 1018–1023
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.-T., Flandrin G., Gallon D. A. G., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-operative Group. Br. J. Haematol. 1976; 33: 451–458
   PubMed Web of Science ®Google Scholar
• Galton D. A. G., Dacie J.V. Classification of the acute leukaemias. Blood Cells 1975; 1: 17–24
   Google Scholar
• Rheingold J.J., Kaufman R., Adelson E., Lear A. Smoldering acute leukemia. N. Engl. J. Med. 1963; 268: 812–815
   PubMed Web of Science ®Google Scholar
• Rheingold J.J. Acute leukemia, its smoldering phase or leukemia never starts on Thursday. J. Am. Med. Assoc 1974; 230: 985–986
   Google Scholar
• Fourth report of the Committee for Clarification of the Nomenclature of Cells and Diseases of the Blood and Blood-forming Organs. Recommended terms and definitions for leukemias and lymphomas. Am. J. Clin. Path. 1950; 20: 571–574
   Google Scholar
• Tivey H. The natural history of untreated acute leukemia. Ann. N. Y. Acad. Sci. 1955; 60: 322–358
   Google Scholar
• Bennett J.M., Catovsky D., Daniel M.-T., Flandrin G., Galton D. A. G., Gralnick H.R., Sultan C. The French-American-British (FAB) Co-operative Group Proposals for the classification of the myelodysplastic syndromes. Br. J. Haematol. 1982; 51: 189–199
   PubMed Web of Science ®Google Scholar
• Hayhoe F. G. J., Cawley J.C. Acute leukemia: cellular morphology, cytochemistry and fine structure. Clin. Haematol. 1972; 1: 49–94
   Google Scholar
• Geary C.G. Clinical annotation. The diagnosis of preleukaemia. Br. J. Haematol. 1983; 55: 1–6
   PubMed Web of Science ®Google Scholar
• Williams W.J. Examination of the blood. Haematology, 3rd edn, W.J. Williams, E. Beutler, A.J. Erslev, M.A. Lichtman. McGraw-Hill, New York 1986; 9–25
   Google Scholar
• Beckmann H., Neth R., Gaedicke G., Landbeck G., Schoch G., Wiegers U., Winkler K. Cytology and cytochemistry of the leukemic cell. Modern Trends in Human Leukemia. Biological, Biochemical, and Virological Aspects, R. Neth, R.C. Gallo, S. Spiegelman, F. Stohlman, Jr. Grune & Stratton, New York 1974; 26–35
   Google Scholar
• Miale J.B. Morphology of blood and bone marrow cells. Laboratory Medicine: Hematology. C. V. Mosby, Saint Louis 1977; 134–272
   Google Scholar
• Sultan A.C. Dysmyelopoetic syndromes, 749-753 in Gralnick, H. R. (moderator): Classification of acute leukemia. Ann. Int. Med. 1977; 87: 740–753
   PubMedGoogle Scholar
• Varela B.L., Chuang C., Woll J.E., Bennett J.M. Modifications in the classification of primary myelodysplastic syndromes: the addition of a scoring system. Hematol. Oncol. 1985; 3: 55–63
   PubMed Web of Science ®Google Scholar
• Weisdorf D.J., Oken M.M., Johnson G.J., Rydell R.E. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukemia. Br. J. Haematol. 1983; 55: 691–700
   PubMed Web of Science ®Google Scholar
• Teerenhovi L., Lintula R. Natural history of myelodysplastic syndromes—Helsinki experience. Scand. J. Haematol. 1986; 36(Supl. 45)102–106
   Google Scholar
• Mufti G.J., Stevens J.R., Oscier D.G., Hamblin T.J., Machin D. Myelodysplastic syndromes: a scoring system of prognostic significance. Br. J. Haematol. 1985; 59: 425–433
   PubMed Web of Science ®Google Scholar
• Tricot G., Vlietinck R., Boogaerts M.A., Hendrickx B., De Wolf-Peeters C., Van den Berghe H., Verwilghen R.L. Prognostic factors in the myelodysplastic syndromes: Importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosome analysis. Br. J. Haematol 1985; 60: 19–32
   PubMed Web of Science ®Google Scholar
• Sanz G.F., Sanz M.A., Vallespi T., Consuelo Cafiizo M., Torrabadella M., Garcia S., Irriguible D., San Miguel J.F. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395–408
   PubMed Web of Science ®Google Scholar
• Aul C., Gatterman N., Heyll A., Germing U., Derigs G., Schneider W. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia 1992; 6: 52–59
   PubMed Web of Science ®Google Scholar
• Mufti G.J. A guide to risk assessment in the primary myelodysplastic syndrome. Hematol./Oncol. Clin, N. Am. 1992; 6: 587–606
   PubMed Web of Science ®Google Scholar
• Estey E., Smith T.L., Keating M.J., McCredie K.B., Gehan E.A., Freireich E.J. Prediction of survival during induction therapy in patients with newly diagnosed acute myeloblastic leukemia. Leukemia 1989; 3: 257–263
   PubMed Web of Science ®Google Scholar
• Foucar K., Langdon R.M., II, Armitage J.O., Olson D.B., Carroll T.J., Jr. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985; 56: 553–561
   PubMed Web of Science ®Google Scholar
• Scoazec J.Y., Imbert M., Crofts M., Jouault H., Juneja S.K., Wernant J.P., Sultan C. Myelodysplastic syndrome or acute myeloid leukemia? A study of 28 cases presenting with borderline features. Cancer 1985; 55: 2390–2394
   PubMed Web of Science ®Google Scholar
• Michels S.D., Samur J., Arthur D.C., Robison L.L., Brunning R.D. Refractory anemia with excess of blasts in transformation. Hematologic and clinical study of 52 patients. Cancer 1989; 64: 2340–2346
   PubMed Web of Science ®Google Scholar
• Goasguen J.E., Garand R., Bizet M., Bremond J.L., Gardais J., Callat M.P., Accard F., Chaperon J. Prognostic factors of myelodysplastic syndromes. A simplified 3-D scoring system. Leuk. Res. 1990; 14: 255–262
   PubMed Web of Science ®Google Scholar
• Vallespí T., Sanz G., Torrabadella M., Irriguible D., Sanz M.A. Auer rods in myelodysplastic syndromes (MDS): presence and significance. Blood 1990; 76(Supl. 1)330a, (abstract)
   PubMedGoogle Scholar
• Seymour J.F., Estey E.H. The prognostic significance of Auer rods in myelodysplasia. Br. J. Haematol. 1993; 85: 67–76
   PubMed Web of Science ®Google Scholar
• Weisdorf D.J., Oken M.M., Johnson G.J., Rydell R.E. Auer rod positive dysmyelopoietic syndrome. Am. J. Haematol 1981; 11: 397–402
   Web of Science ®Google Scholar
• Seigneurin D., Audhuy B. Auer rods in refractory anemia with excess of blasts: Presence and significance. Am. J. Clin. Path. 1983; 80: 359–362
   PubMed Web of Science ®Google Scholar
• Mertelsmann R., Thaler H.T., To L., Gee T.S., McKenzie S., Schauer P., Friedman A., Arlin Z., Cirrincione C., Clarkson B. Morphologic classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia. Blood 1980; 56: 773–781
   PubMed Web of Science ®Google Scholar
• Aul C., Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989; 64: 1812–1818
   PubMed Web of Science ®Google Scholar
• Maddox A.M., Keating M.J., Smith T.L., Speer J., Cork M.A., Trujillo J.M., McCredie K.B., Freireich E.J. Prognostic factors for survival of 194 patients with low infiltrate leukemia. Leuk. Res. 1986; 10: 995–1006
   PubMed Web of Science ®Google Scholar
• Fenaux P., Morel P., Rose C., Lai J.L., Jouet J.P., Bauters F. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy. Br. J. Haematol. 1991; 77: 497–501
   PubMed Web of Science ®Google Scholar
• Yamada T., Ogata K., Miyake K., Futaki M., An E., Inokuchi K., Ito T., Gomi S., Tanabe Y., Ohki I., Kuwabara T., Dan K., Nomura T. Small-dose cytarabine in the treatment of myelodysplastic syndrome. Myelodysplastic Syndrome and Cytokines, T. Miyazaki, F. Takau, H. Uchino. Elsevier, Amsterdam 1991; 301–304
   Google Scholar
• Hellström-Lindberg E., Robert K.H., Gahrton G., Lindberg G., Forsblom A.M., Kocköst Y. Å. A predictive model for the clinical response to low dose ara-C: A study of 102 patients with myelodysplastic syndromes or acute leukemia. Br. J. Haematol. 1992; 81: 503–511
   PubMed Web of Science ®Google Scholar
• Miller K.B., Kyungmann K., Morrison F.S., Winter J.N., Bennett J.M., Neiman R.S., Head D.R., Cassileth P.A., O'Connell M.J. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann. Hematol. 1992; 65: 162–168
   PubMed Web of Science ®Google Scholar
• Estey E.H., Keating M.J., Dixon D.O., Trujillo J.M., McCredie K.B., Freireich E.J. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia. Hematol. Path. 1987; 1: 203–208
   PubMedGoogle Scholar